Torray Investment Partners LLC Raises Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Torray Investment Partners LLC grew its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 66.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 122,095 shares of the biotechnology company’s stock after purchasing an additional 48,671 shares during the quarter. Torray Investment Partners LLC owned approximately 0.13% of Rocket Pharmaceuticals worth $1,535,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Rocket Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,292 shares of the biotechnology company’s stock worth $61,000 after buying an additional 582 shares during the period. KBC Group NV lifted its position in Rocket Pharmaceuticals by 159.6% in the fourth quarter. KBC Group NV now owns 5,475 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 3,366 shares during the period. Strategic Financial Concepts LLC acquired a new stake in Rocket Pharmaceuticals in the fourth quarter valued at about $141,000. Private Advisor Group LLC acquired a new stake in Rocket Pharmaceuticals in the fourth quarter valued at about $166,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in Rocket Pharmaceuticals by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 19,329 shares of the biotechnology company’s stock valued at $243,000 after purchasing an additional 1,824 shares during the period. Hedge funds and other institutional investors own 98.39% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on RCKT. Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 price objective on shares of Rocket Pharmaceuticals in a research report on Tuesday, November 19th. Canaccord Genuity Group reduced their price target on shares of Rocket Pharmaceuticals from $39.00 to $36.00 and set a “buy” rating for the company in a research report on Monday. Leerink Partners reduced their price target on shares of Rocket Pharmaceuticals from $46.00 to $44.00 and set an “outperform” rating for the company in a research report on Tuesday, November 19th. Jefferies Financial Group started coverage on shares of Rocket Pharmaceuticals in a research report on Wednesday, December 18th. They set a “buy” rating and a $29.00 price target for the company. Finally, Wedbush started coverage on shares of Rocket Pharmaceuticals in a research report on Monday, December 30th. They set an “outperform” rating and a $32.00 price target for the company. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.30.

Rocket Pharmaceuticals Trading Down 7.0 %

Shares of RCKT opened at $8.79 on Tuesday. The stock has a market cap of $801.27 million, a price-to-earnings ratio of -3.20 and a beta of 0.98. The company has a debt-to-equity ratio of 0.06, a current ratio of 6.05 and a quick ratio of 6.05. Rocket Pharmaceuticals, Inc. has a 1-year low of $8.78 and a 1-year high of $30.94. The firm has a 50 day simple moving average of $10.89 and a 200-day simple moving average of $14.66.

Rocket Pharmaceuticals (NASDAQ:RCKT) last released its earnings results on Monday, March 3rd. The biotechnology company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.06. Equities analysts forecast that Rocket Pharmaceuticals, Inc. will post -2.83 EPS for the current fiscal year.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.